| 000 | 01706 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515091347.0 | ||
| 264 | 0 | _c20071206 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a1359-6535 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRen, Guang-Li | |
| 245 | 0 | 0 |
_aThe short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains. _h[electronic resource] |
| 260 |
_bAntiviral therapy _c2007 |
||
| 300 |
_a865-76 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiviral Agents _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDNA, Viral |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 | _aGene Expression Regulation, Viral |
| 650 | 0 | 4 | _aGenetic Vectors |
| 650 | 0 | 4 |
_aHepatitis B Surface Antigens _xisolation & purification |
| 650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLamivudine _xpharmacology |
| 650 | 0 | 4 |
_aLiver _xcytology |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 | _aRNA Interference |
| 650 | 0 | 4 |
_aRNA Polymerase II _xmetabolism |
| 650 | 0 | 4 | _aRNA, Messenger |
| 650 | 0 | 4 |
_aRNA, Small Interfering _xtherapeutic use |
| 700 | 1 | _aFang, Ying | |
| 700 | 1 | _aMa, Heng-Hao | |
| 700 | 1 | _aLei, Ying-Feng | |
| 700 | 1 | _aWang, Dan | |
| 700 | 1 | _aXu, Man-Chun | |
| 700 | 1 | _aWang, Ping-Zhong | |
| 700 | 1 | _aHuang, Chang-Xing | |
| 700 | 1 | _aNie, Oing-He | |
| 700 | 1 | _aSun, Yong-Tao | |
| 700 | 1 | _aBai, Xue-Fan | |
| 773 | 0 |
_tAntiviral therapy _gvol. 12 _gno. 6 _gp. 865-76 |
|
| 999 |
_c17447640 _d17447640 |
||